Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now
09:16am, Thursday, 22'nd Aug 2024
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segments raise optimism. However, macro issues raise concerns.
$BKYI BIO-key's PortalGuard Identity Access Management Solution & Identity-Bound Biometrics Are Now Available on the Amazon Web Services (AWS) Marketplace
BIO-key Reports Reduced Net Loss and Cash Used in Operations on Lower Q2'24 Revenues; Hosts Investor Call Thu. Aug. 15th at 10am ET
04:30pm, Wednesday, 14'th Aug 2024
HOLMDEL, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featurin
Bio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure
12:16pm, Monday, 12'th Aug 2024
Bio-Rad (BIO) is experiencing weaker sales in Asia as China is currently entangled in a challenging research funding environment, and Japan, too, is facing constrained funding issues.
Identity and Access Management Solutions Provider BIO-key Hosts Q2 Investor Call Thursday, August 15th at 10am ET
10:35am, Monday, 12'th Aug 2024
HOLMDEL, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of Identity and Access Management and Identity-Bound Biometric solutions, will host
BIO-TECHNE DECLARES DIVIDEND
06:30am, Wednesday, 07'th Aug 2024
MINNEAPOLIS , Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2
BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS
06:30am, Wednesday, 07'th Aug 2024
MINNEAPOLIS , Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2024. Fourth Quarter FY2024 Highlights Four
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered
11:22am, Friday, 02'nd Aug 2024
Bio-Rad (BIO) witnesses growth in the second quarter across the Clinical Diagnostics segment, primarily driven by an increased demand for quality control and blood typing products.
Bio-Rad Laboratories, Inc. (BIO) Q2 2024 Earnings Call Transcript
10:47pm, Thursday, 01'st Aug 2024
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Norman Schwartz - Chairman of
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings Estimates
06:26pm, Thursday, 01'st Aug 2024
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $3.11 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $3 per share a year ago.
Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products
05:56pm, Thursday, 01'st Aug 2024
Bio-Rad Laboratories cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients.
Bio-Rad Reports Second-Quarter 2024 Financial Results
04:15pm, Thursday, 01'st Aug 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t
What's in Store for These 4 MedTech Stocks in Q2 Earnings?
01:01pm, Wednesday, 31'st Jul 2024
Here is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.
BIO-TECHNE ANNOUNCES NEXT-GENERATION HIGH THROUGHPUT SIMPLE WESTERN SYSTEM
07:00am, Wednesday, 31'st Jul 2024
MINNEAPOLIS , July 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce the launch of the Leo™ System. This next-generation Simple Western™ instrument offers high
All You Need to Know About Bio-Rad (BIO) Rating Upgrade to Buy
01:00pm, Tuesday, 30'th Jul 2024
Bio-Rad (BIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
